Investigation of the potential antitumor radioactive complex of platinum(II) with tetracycline

Abstract

The proposal of this work was to investigate the effect of the radioactive complex of platinum(II) with tetracycline, [PtCl2(C22H24N2O8)]*, or [Tc–Pt(II)]*, on K562 cells—blood human cells of leukemia—and verify if the internal radio-chemotherapy would be able to produce additional effects compared with the non-labelled complex, [PtCl2(C22H24N2O8)], or [Tc–Pt(II)]. The concentration required to inhibit 50 % of cellular growth, (IC50), was 2.5 ± 0.2 µM for [Tc–Pt(II)]* and 14.5 ± 0.9 µM for the non-labelled molecule [Tc–Pt(II)]. This result suggest that the [Tc–Pt(II)]* could be a potent radiosensitizer evoking a supra additive effect. Treatment using the internal radio-chemotherapy may be a useful alternative to reduce the drug concentration required for effective inhibition of the tumor growth.